Company registration number 09429979 (England and Wales)
BAYAM MEDICAL LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
PAGES FOR FILING WITH REGISTRAR
BAYAM MEDICAL LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 5
BAYAM MEDICAL LTD
BALANCE SHEET
AS AT
28 FEBRUARY 2024
28 February 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
1,422
1,671
Current assets
Cash at bank and in hand
73,767
65,493
Creditors: amounts falling due within one year
5
(5,694)
(6,129)
Net current assets
68,073
59,364
Net assets
69,495
61,035
Capital and reserves
Called up share capital
5
5
Profit and loss reserves
69,490
61,030
Total equity
69,495
61,035

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 28 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 5 September 2024 and are signed on its behalf by:
Dr F Bayam
Dr L Bayam
Director
Director
Company registration number 09429979 (England and Wales)
BAYAM MEDICAL LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 March 2022
5
48,925
48,930
Year ended 28 February 2023:
Profit and total comprehensive income
-
16,105
16,105
Dividends
-
(4,000)
(4,000)
Balance at 28 February 2023
5
61,030
61,035
Year ended 28 February 2024:
Profit and total comprehensive income
-
13,460
13,460
Dividends
-
(5,000)
(5,000)
Balance at 28 February 2024
5
69,490
69,495
BAYAM MEDICAL LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 3 -
1
Accounting policies
Company information

Bayam Medical Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 1a Davyhulme Circle, Urmston, Manchester, Greater Manchester, M41 0ST.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
15%
Fixtures and fittings
15%
Computers
15%

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

BAYAM MEDICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
1
Accounting policies
(Continued)
- 4 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Judgements and key sources of estimation uncertainty
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
-
0
BAYAM MEDICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 5 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 March 2023 and 28 February 2024
4,466
Depreciation and impairment
At 1 March 2023
2,795
Depreciation charged in the year
249
At 28 February 2024
3,044
Carrying amount
At 28 February 2024
1,422
At 28 February 2023
1,671
5
Creditors: amounts falling due within one year
2024
2023
£
£
Corporation tax
3,216
3,847
Other creditors
2,478
2,282
5,694
6,129
2024-02-282023-03-01false05 September 2024CCH SoftwareCCH Accounts Production 2024.100No description of principal activityDr Fatma BayamDr Levent Bayamfalsefalse094299792023-03-012024-02-28094299792024-02-28094299792023-02-2809429979core:OtherPropertyPlantEquipment2024-02-2809429979core:OtherPropertyPlantEquipment2023-02-2809429979core:CurrentFinancialInstrumentscore:WithinOneYear2024-02-2809429979core:CurrentFinancialInstrumentscore:WithinOneYear2023-02-2809429979core:CurrentFinancialInstruments2024-02-2809429979core:CurrentFinancialInstruments2023-02-2809429979core:ShareCapital2024-02-2809429979core:ShareCapital2023-02-2809429979core:RetainedEarningsAccumulatedLosses2024-02-2809429979core:RetainedEarningsAccumulatedLosses2023-02-2809429979core:ShareCapital2022-02-2809429979core:RetainedEarningsAccumulatedLosses2022-02-2809429979bus:Director12023-03-012024-02-2809429979bus:Director22023-03-012024-02-2809429979core:RetainedEarningsAccumulatedLosses2022-03-012023-02-28094299792022-03-012023-02-2809429979core:RetainedEarningsAccumulatedLosses2023-03-012024-02-2809429979core:PlantMachinery2023-03-012024-02-2809429979core:FurnitureFittings2023-03-012024-02-2809429979core:ComputerEquipment2023-03-012024-02-2809429979core:OtherPropertyPlantEquipment2023-02-2809429979core:OtherPropertyPlantEquipment2023-03-012024-02-2809429979bus:PrivateLimitedCompanyLtd2023-03-012024-02-2809429979bus:SmallCompaniesRegimeForAccounts2023-03-012024-02-2809429979bus:FRS1022023-03-012024-02-2809429979bus:AuditExemptWithAccountantsReport2023-03-012024-02-2809429979bus:FullAccounts2023-03-012024-02-28xbrli:purexbrli:sharesiso4217:GBP